دورية أكاديمية
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
| العنوان: | Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. |
|---|---|
| المؤلفون: | Zeymer U; Klinikum Ludwigshafen, Medizinische Klinik B and Institut für Herzinfarktforschung, Bremserstrasse 79, 67063 Ludwigshafen-am-Rhein, Germany., Clark AL; Castle Hill Hospital, Kingston Upon Hull, Castle Rd, Cottingham HU16 5JQ, United Kingdom., Barrios V; Department of Cardiology, Ramon y Cajal Hospital, Ctra. de Colmenar Viejo km. 9,100 28034 Madrid, Spain., Damy T; Department of Cardiology, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000 Créteil, France., Drożdż J; Department Cardiology Medical University of Lodz, Poland 92-213 Lodz, Pomorska 251, Poland., Fonseca C; Hospital de Sao Francisco Xavier, Estrada Forte do Alto do Duque, 1449-005, Lisbon, Portugal., Lund LH; Department of Medicine, Unit of Cardiology, Karolinska Institutet and Karolinska University HospitalFoU Tema Hjärta Kärl, Eugeniavägen 3, Norrbacka, S1:02, 171 76 Stockholm, Sweden., Kalus S; GKM Gesellschaft für Therapieforschung mbH, Lessingstr. 14, 80336 Munich, Germany., Ferber PC; Novartis Pharma AG, Basel, Switzerland., Hussain RI; Arxx Therapeutics, Gaustadalléen 21, 0349 Oslo, Norway.; Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen, Denmark., Koch C; Novartis Pharma AG, Basel, Switzerland., Maggioni AP; Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Via La Marmora 34, 50121 Florence, Italy.; Maria Cecilia Hospital, GVM Care & Research, Via Corriera, 1, 48033 Cotignola RA, Italy. |
| المصدر: | European heart journal. Quality of care & clinical outcomes [Eur Heart J Qual Care Clin Outcomes] 2022 Jun 06; Vol. 8 (4), pp. 469-477. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101677796 Publication Model: Print Cited Medium: Internet ISSN: 2058-1742 (Electronic) Linking ISSN: 20581742 NLM ISO Abbreviation: Eur Heart J Qual Care Clin Outcomes Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Oxford University Press, [2015]- |
| مواضيع طبية MeSH: | Heart Failure*/drug therapy , Heart Failure*/epidemiology , Ventricular Dysfunction, Left*, Adolescent ; Adult ; Aged ; Aminobutyrates/therapeutic use ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors ; Biphenyl Compounds ; Humans ; Registries ; Stroke Volume ; Tetrazoles/therapeutic use ; Treatment Outcome ; Valsartan ; Ventricular Function, Left |
| مستخلص: | Aims: To compare baseline characteristics of patients with heart failure with reduced ejection fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on conventional heart failure (HF)-treatment in a European out-patient setting. Methods and Results: Between July 2016 and July 2019, ARIADNE enrolled 8787 outpatients aged ≥18 years with HFrEF from 17 European countries. Choice of therapy was solely at the investigators' discretion. In total, 4173 patients were on conventional HF-treatment (non-S/V group), while 4614 patients were on sacubitril/valsartan either at enrolment or started sacubitril/valsartan within 1 month of enrolment (S/V group). Of these, 2108 patients started sacubitril/valsartan treatment ±1 month around enrolment [restricted S/V (rS/V) group]. The average age of the patients was 68 years. Patients on S/V were more likely to have New York Heart Association (NYHA) class III or IV symptoms (50.3%, 44.6%, 32.1% in rS/V, S/V, and non-S/V, respectively) and had lower left ventricular ejection fraction (LVEF; 32.3%, 32.7%, and 35.4% in rS/V, S/V, and non-S/V, respectively; P < 0.0001). The most frequently received HF treatments were angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB; ∼84% in non-S/V), followed by β-blockers (∼80%) and mineralocorticoid receptor antagonists (MRAs; 53%). The use of triple HF therapy (ACEI/ARB/angiotensin receptor neprilysin inhibitor with β-blockers and MRA) was higher in the S/V groups than non-S/V group (48.2%, 48.2%, and 40.2% in rS/V, S/V, and non-S/V, respectively). Conclusion: In this large multinational HFrEF registry, patients receiving sacubitril/valsartan tended to be younger with lower LVEF and higher NYHA class. Fewer than half of the patients received triple HF therapy. (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.) |
| فهرسة مساهمة: | Keywords: ARNI; Guideline adherence; Heart failure with reduced ejection fraction; Outpatient; Real-world evidence; sacubitril/valsartan |
| المشرفين على المادة: | 0 (Aminobutyrates) 0 (Angiotensin Receptor Antagonists) 0 (Angiotensin-Converting Enzyme Inhibitors) 0 (Biphenyl Compounds) 0 (Tetrazoles) 17ERJ0MKGI (sacubitril) 80M03YXJ7I (Valsartan) |
| تواريخ الأحداث: | Date Created: 20210316 Date Completed: 20220608 Latest Revision: 20220609 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1093/ehjqcco/qcab019 |
| PMID: | 33725113 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2058-1742 |
|---|---|
| DOI: | 10.1093/ehjqcco/qcab019 |